Modified FOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab beyond first progression in advanced colorectal cancer: CCOG-0801 study. A phase I/II study of biweekly XELIRI plus bevacizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results